Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Becton, Dickinson and Company    BDX

BECTON, DICKINSON AND COMPANY

(BDX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

BECTON, DICKSON AND COMPANY ALERT: Bragar Eagel & Squire, P.C. is Investigating Becton, Dickson and Company on Behalf of Stockholders and Encourages Investors to Contact the Firm

share with twitter share with LinkedIn share with facebook
share via e-mail
02/10/2020 | 08:27pm EDT

Bragar Eagel & Squire, P.C., a nationally recognized shareholder law firm, is investigating potential claims against Becton, Dickson and Company (NYSE: BDX) on behalf of Becton stockholders. Our investigation concerns whether Becton has violated the federal securities laws and/or engaged in other unlawful business practices.

Click here to participate in the action.

On February 6, 2020, Becton lowered its fiscal 2020 guidance, expecting revenue to increase by only 1.5 to 2.5 percent, “to reflect the impact of the remediation effort and anticipated loss of sales of the Alaris infusion system.” According to the Company, the software remediation plan for the Alaris system “will require additional regulatory filings,” and existing customers would have “access to the Alaris System under medical necessity.”

On this news, Becton's share price fell as much as $33.74, or over 13%, on February 6, 2020 to close at $252.25 per share.

If you purchased or otherwise acquired Becton shares and suffered a loss, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Melissa Fortunato or Marion Passmore by email at investigations@bespc.com, or telephone at (646) 860-9156, or by filling out this contact form. There is no cost or obligation to you.

About Bragar Eagel & Squire, P.C.:

Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.


© Business Wire 2020
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on BECTON, DICKINSON AND COMP
04/06BECTON DICKINSON AND : BD Announces Live Webcast Of Second Fiscal Quarter Earnin..
PR
04/06BECTON DICKINSON AND : BD, BioGX Announce FDA Emergency Use Authorization for Ne..
AQ
04/03BECTON DICKINSON AND : BD, BioGX Announce FDA Emergency Use Authorization for Ne..
PR
04/03BECTON DICKINSON AND : BD, BioGX Get FDA Emergency Authorization for Three-Hour ..
DJ
04/02BECTON DICKINSON & CO : Entry into a Material Definitive Agreement, Creation of ..
AQ
04/02BECTON DICKINSON AND : BD, BioMedomics Announce Launch of Rapid Serology Test to..
AQ
04/01HENRY SCHEIN : Harry Schein Exclusive Distributor of Point-of-Care Covid-19 Test
DJ
04/01BECTON DICKINSON AND : BD, Bio Medomics Announce Launch of Rapid Serology Test t..
AQ
03/31BECTON DICKINSON AND : BioMedomics to Release Rapid Covid-19 Detection Test
DJ
03/31BECTON DICKINSON AND : BD, BioMedomics Announce Launch of Rapid Serology Test to..
PR
More news
Financials (USD)
Sales 2020 17 430 M
EBIT 2020 4 481 M
Net income 2020 1 938 M
Debt 2020 16 579 M
Yield 2020 1,40%
P/E ratio 2020 31,3x
P/E ratio 2021 23,4x
EV / Sales2020 4,80x
EV / Sales2021 4,38x
Capitalization 67 102 M
Chart BECTON, DICKINSON AND COMPANY
Duration : Period :
Becton, Dickinson and Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BECTON, DICKINSON AND COMP
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 18
Average target price 266,50  $
Last Close Price 247,45  $
Spread / Highest target 17,2%
Spread / Average Target 7,70%
Spread / Lowest Target -5,44%
EPS Revisions
Managers
NameTitle
Thomas E. Polen President, Chief Executive Officer & Director
Vincent A. Forlenza Executive Chairman
Christopher R. Reidy Chief Financial Officer, CAO & EVP-Administration
John A. DeFord Chief Technology Officer & Executive VP
William R. Sigmund Chief Medical Officer & EVP
Sector and Competitors